Dose escalation trials for identifying the maximum tolerable dose (MTD) is commonly considered in phase 1 cancer clinical research. For this purpose, an algorithm-based design such as a standard escalation design with traditional escalation rule (TER) and a model-based design such as the method of continued reassessment method (CRM) under a well-established dose toxicity model are commonly employed. In practice, relative merits and limitations of these two different types of designs are not fully understood. Besides, most dose escalation studies do not provide scientific justification for sample size and design selection. In this article, the validity and efficiency of these two different types of study designs are evaluated based on the cr...
In oncology, dose escalation is often carried out to search for the maximum tolerated dose (MTD) in ...
Background: Statistical simulations have consistently demonstrated that new dose-escalation designs ...
Despite an enormous and growing statistical literature, formal procedures for dose-finding are only ...
Phase I trials are the cornerstone of cancer drug development, and the goal of phase I dose-finding ...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
Statistical simulations have consistently demonstrated that new dose-escalation designs such as acce...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
BACKGROUND: Statistical simulations have consistently demonstrated that new dose-escalation designs ...
This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different do...
This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different do...
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose th...
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose th...
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose th...
In oncology, dose escalation is often carried out to search for the maximum tolerated dose (MTD) in ...
Background: Statistical simulations have consistently demonstrated that new dose-escalation designs ...
Despite an enormous and growing statistical literature, formal procedures for dose-finding are only ...
Phase I trials are the cornerstone of cancer drug development, and the goal of phase I dose-finding ...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
Statistical simulations have consistently demonstrated that new dose-escalation designs such as acce...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
BACKGROUND: Statistical simulations have consistently demonstrated that new dose-escalation designs ...
This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different do...
This paper reviews Bayesian procedures for phase 1 dose-escalation studies and compares different do...
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose th...
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose th...
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose th...
In oncology, dose escalation is often carried out to search for the maximum tolerated dose (MTD) in ...
Background: Statistical simulations have consistently demonstrated that new dose-escalation designs ...
Despite an enormous and growing statistical literature, formal procedures for dose-finding are only ...